Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Inactive state-selective KRAS(G12C) inhibitors1,2,3,4,5,6,7,8 demonstrate a 30–40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class mutant GTPase inhibitors remains under investigation. Here we evaluated matched pre-treatment and post-treatment specimens from 43 patients treated with the KRAS(G12C) inhibitor sotorasib.
Resolution Bioscience, Inc., today announced that its Resolution HRD™ liquid biopsy assay is being developed as a companion diagnostic for niraparib, a PARP inhibitor that is currently being investigated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) as part of a research collaboration with Janssen Research & Development, LLC (Janssen).
1. Introduction Tumor genotyping has become an integral part of identifying actionable, targetable mutations and administering personalized therapy for patients with advanced non-small cell lung cancer (NSCLC). Non-invasive genotyping assays for plasma cell free DNA (cfDNA) have been adopted broadly for care of advanced NSCLC based on data indicating a high positive predictive value for actionable mutations.[1x[1]Aggarwal, C, Thompson, JC, Black, TA et al.
Background: Genomic profiling of tumor tissue at diagnosis is the standard of care for various cancers. Profiling of circulating-tumor DNA (ctDNA) found in peripheral blood of cancer patients is an attractive alternative to invasive tissue biopsy. We describe the use of a comprehensive NGS sequencing assay of ctDNA in the clinical setting.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
